Can a positive Lyme screening antibody with equivocal IgM/IgG confirmatory results distinguish active infection from past exposure or cross-reactivity?

Interpreting Lyme disease serology requires navigating the complexities of the standard two-tiered testing (STTT) algorithm, which involves a high-sensitivity screening assay followed by a high-specificity confirmatory test. When a positive or elevated screening result is paired with equivocal confirmatory findings, the results are often clinically ambiguous.

Clinical and diagnostic evidence

The discrepancy between screening and confirmatory assays is a well-documented phenomenon, occurring in approximately 4% to 19% of cases.

• Assay variability: Discordance frequently arises because the initial screening (usually an ELISA or IFA) is designed for maximum sensitivity, while the confirmatory Western blot (immunoblot) requires meeting specific, stringent band-counting criteria (e.g., 2 out of 3 IgM bands or 5 out of 10 IgG bands).
• Diagnostic limitations: Serological results do not correlate directly with disease activity. IgG antibodies can persist for decades after the resolution of infection, meaning a positive or equivocal result cannot distinguish between a current, active infection and a past exposure.
• Predictive value: In the absence of characteristic clinical symptoms, the positive predictive value of serology remains low. Consequently, laboratory data alone is insufficient for a definitive diagnosis.

Mechanistic explanations

The underlying reasons for these diagnostic challenges are rooted in the molecular and immunological nature of the assays.

• Antigen composition: Many screening assays use whole-cell lysates (WCL) of Borrelia burgdorferi. These lysates contain antigens that may share epitopes with other pathogens or human proteins, leading to cross-reactivity.
• Cross-reactivity pathways: False positives or equivocal blots can be triggered by antibodies from other spirochetal infections (e.g., syphilis), viral infections (e.g., EBV, CMV), or autoimmune conditions (e.g., rheumatoid factor).
• Polyclonal B-cell activation: Certain systemic infections can cause a broad stimulation of B-cells, producing low-affinity antibodies that react with Lyme antigens, further complicating the interpretation of equivocal results.
• Antibody avidity: In the early stages of infection, antibody avidity may be too low to produce the distinct, high-intensity bands required for a "positive" Western blot, resulting in an equivocal readout despite an elevated screen.

Bottom line

A positive Lyme screen with equivocal confirmatory results is a common diagnostic scenario driven by assay design differences and immune cross-reactivity. These findings indicate exposure or immunological activity but cannot, by themselves, differentiate between active infection, past exposure, or false-positive cross-reactivity. Clinical correlation with symptoms and history is essential for diagnosis.